Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.

Science Translational Medicine
Timothy L LochmannAnthony C Faber

Abstract

High-risk neuroblastoma is often distinguished by amplification of MYCN and loss of differentiation potential. We performed high-throughput drug screening of epigenetic-targeted therapies across a large and diverse tumor cell line panel and uncovered the hypersensitivity of neuroblastoma cells to GSK-J4, a small-molecule dual inhibitor of lysine 27 of histone 3 (H3K27) demethylases ubiquitously transcribed tetratricopeptide repeat, X chromosome (UTX), and histone demethylase Jumonji D3 (JMJD3). Mechanistically, GSK-J4 induced neuroblastoma differentiation and endoplasmic reticulum (ER) stress, with accompanying up-regulation of p53 up-regulated modulator of apoptosis (PUMA) and induction of cell death. Retinoic acid (RA)-resistant neuroblastoma cells were sensitive to GSK-J4. In addition, GSK-J4 was effective at blocking the growth of chemorefractory and patient-derived xenograft models of high-risk neuroblastoma in vivo. Furthermore, GSK-J4 and RA combination increased differentiation and ER stress over GSK-J4 effects and limited the growth of neuroblastomas resistant to either drug alone. In MYCN-amplified neuroblastoma, PUMA induction by GSK-J4 sensitized tumors to the B cell lymphoma 2 (BCL-2) inhibitor venetoclax, demonstr...Continue Reading

References

Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Mar 4, 2003·Nature Reviews. Cancer·Garrett M Brodeur
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Feb 3, 2009·Nature Genetics·Paulina Kolasinska-ZwierzJulie Ahringer
Jul 31, 2009·Oncogene·J Yu, L Zhang
Oct 1, 2010·The New England Journal of Medicine·Alice L YuUNKNOWN Children's Oncology Group
Dec 23, 2011·Oncotarget·Katrina Tatton-BrownNazneen Rahman
Dec 27, 2011·Biochemical and Biophysical Research Communications·Lihua LiuShengyun Fang
Jan 31, 2012·Nature Genetics·Gang WuUNKNOWN St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project
Mar 15, 2012·JAMA : the Journal of the American Medical Association·Nai-Kong V CheungUNKNOWN St Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project
Apr 5, 2012·Nature Reviews. Genetics·Eric L Greer, Yang Shi
May 17, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elizabeth R Lawlor, Carol J Thiele
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Oct 3, 2013·Cold Spring Harbor Perspectives in Medicine·Miller Huang, William A Weiss
Oct 4, 2014·Nature·Bo HeinemannKristian Helin
May 1, 2015·PloS One·Shinsuke MatsuzakiTaiichi Katayama
May 6, 2015·Nature Medicine·Catherine S GrassoMichelle Monje
Jun 30, 2015·Nature Genetics·Alexander SchrammJohannes H Schulte
Jul 8, 2015·Nature Medicine·Catherine S GrassoMichelle Monje
Aug 8, 2015·Molecular Cancer·Mayumi HigashiGarrett M Brodeur
Oct 13, 2015·Cell Reports·Mattheus C B WielengaGijs R van den Brink
Nov 5, 2015·Advances in Experimental Medicine and Biology·Maria Antonietta IsgròRoberto Scatena
Dec 21, 2016·PLoS Genetics·Olivia M Padovan-MerharShakeel Modak

❮ Previous
Next ❯

Citations

Jan 11, 2019·International Journal of Cancer. Journal International Du Cancer·Wolfgang A SchulzAnnemarie Greife
Feb 14, 2019·Expert Opinion on Therapeutic Targets·Tyler S McCannPaul Jedlicka
Nov 9, 2019·Protein & Cell·Xiangxian ZhangXiawei Wei
Jul 15, 2020·European Journal of Immunology·Frank M DavisKatherine A Gallagher
Oct 12, 2018·The New England Journal of Medicine·Steven G DuBois, Julie R Park
Jun 23, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hiroaki KatagiRintaro Hashizume
Jan 7, 2021·Cancer Metastasis Reviews·Irfete S Fetahu, Sabine Taschner-Mandl
Dec 20, 2020·Cancers·Pasquale SaggeseClaudio Scafoglio
Jan 23, 2021·International Journal of Molecular Sciences·Anna SanchezDominique Bernard-Gallon
Jul 6, 2021·Frontiers in Genetics·Gaya Punnia-MoorthyJessamy Tiffen
Jun 6, 2021·Molecular Cancer Therapeutics·Krista M DaltonAnthony C Faber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.